The Application of Ursodeoxycholic Acid for the Prevention of Novel Coronavirus Infections

Evaluation of the efficacy and safety of ursodeoxycholic acid in blocking the transmission of infectious novel coronaviruses in a population of medical workers

Inclusion Criteria:Age 18 - 65 years old.No restriction on gender.Medical-related personnel (working hours >20 hours per week) serving during the COVID-19 outbreak, including physicians, nurses, medical technicians, administrators, and medical studentsCOVID-19 nucleic acid test negative within 48 hoursSign the informed consent formExclusion Criteria:Exhibit COVID-19 symptoms, including fever, muscle pain, headache, cough, sore throat, and loss of smell and tastePrevious infection with novel coronavirus within 6 monthsPrevious (past 30 days), current or planned (during the study period) use of immunomodulatory-related drugsThose with allergy or intolerance to ursodeoxycholic acid, gallbladder or bile duct disease, severe liver failure, or liver function impairmentPregnancy and lactationUse of drugs with which ursodeoxycholic acid is contraindicatedOther reported health conditions that make participation in the study not in the best interest of the individual